2-(4-cyclopropyl-1h-pyrazol-1-yl)acetic acid
![]() |
- $45 - $2222
- Product name: 2-(4-cyclopropyl-1h-pyrazol-1-yl)acetic acid
- CAS: 1402411-46-4
- MF: C8H10N2O2
- MW: 166.18
- EINECS:
- MDL Number:
- Synonyms:2-(4-cyclopropyl-1h-pyrazol-1-yl)acetic acid;1H-Pyrazole-1-acetic acid, 4-cyclopropyl-
4 prices
Selected condition:
Brand
- AK Scientific
- Alichem
- Crysdot
- TRC
Package
- 10mg
- 1g
- 5g
- ManufacturerAK Scientific
- Product number9788DZ
- Product description2-(4-Cyclopropyl-1H-pyrazol-1-yl)aceticacid
- Packaging5g
- Price$2222
- Updated2021-12-16
- Buy
- ManufacturerAlichem
- Product number1402411464
- Product description2-(4-Cyclopropyl-1h-pyrazol-1-yl)aceticacid
- Packaging1g
- Price$830.55
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11264221
- Product description2-(4-Cyclopropyl-1H-pyrazol-1-yl)aceticacid 97%
- Packaging1g
- Price$434
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB425183
- Product description2-(4-cyclopropyl-1H-pyrazol-1-yl)aceticacid
- Packaging10mg
- Price$45
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 9788DZ | 2-(4-Cyclopropyl-1H-pyrazol-1-yl)aceticacid | 5g | $2222 | 2021-12-16 | Buy |
Alichem | 1402411464 | 2-(4-Cyclopropyl-1h-pyrazol-1-yl)aceticacid | 1g | $830.55 | 2021-12-16 | Buy |
Crysdot | CD11264221 | 2-(4-Cyclopropyl-1H-pyrazol-1-yl)aceticacid 97% | 1g | $434 | 2021-12-16 | Buy |
TRC | B425183 | 2-(4-cyclopropyl-1H-pyrazol-1-yl)aceticacid | 10mg | $45 | 2021-12-16 | Buy |
Properties
Boiling point :364.4±25.0 °C(Predicted)
Density :1.45±0.1 g/cm3(Predicted)
pka :3.67±0.10(Predicted)
Density :1.45±0.1 g/cm3(Predicted)
pka :3.67±0.10(Predicted)
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|